Hemostasis Innovation is Here.

HIT testing in minutes

The on-demand solution that saves more than time



werfen

The first on-demand, fully automated assay for HIT antibody detection on Hemostasis systems

Simple to use, fast results

- Fully automated, liquid, ready-to-use
- Results available on-demand, 24 hours/day, 7 days/week
- Results in minutes; minimizes time to treatment decisions

Analytical excellence

- Detects anti-Platelet Factor 4-heparin (anti-PF4-H) antibodies
- Dedicated controls for complete quality management
- Excellent agreement with commercially available ELISA methods

Efficient

- Significantly reduces staff time
- Reduces costs



Heparin-Induced Thrombocytopenia (HIT) overview

HIT is a severe adverse reaction to heparin

Causes

- HIT is associated with both unfractionated (UFH) and low molecular weight heparin (LMWH) administration
- HIT occurs when UFH or LMWH treatments cause an autoimmune reaction, triggering antibodies to activate platelets and initiate the formation of blood clots, resulting in venous and/or arterial thrombosis

Prevalence

- HIT is one of the most prevalent adverse drug effects, due to the number of patients receiving heparin therapy[1]
- 0.2–2.0% of patients treated with heparin (up to 12 million patients/year in the U.S. alone) develop HIT

Suspect HIT

When a patient treated with UFH or LMWH experiences:

- Platelet-count fall >50% vs. baseline
- Venous and/or arterial thrombosis
- Skin necrosis
- Anaphylactic reactions

Antibody detection

- Anti-PF4-H is the most critical antibody in patients with HIT
- PF4, a chemokine with very high affinity for heparin, forms a large immunocomplex with anti-PF4-H antibodies, leading to platelet activation
- The presence of anti-PF4-H antibodies does not always cause HIT
- A negative result for an anti-PF4-H antibody test can support the clinical decision to exclude HIT


Clinical presentations of HIT

- ***Typical-onset:*** platelet-count fall within 5–10 days after heparin administration, significantly increasing risk of thrombosis and other adverse events
- ***Rapid-onset:*** abrupt platelet-count fall (generally within 24 hours), typically following recent heparin administration
- ***Delayed-onset:*** often the most clinically severe, occurs several days after heparin discontinuation. HIT is considered a transient autoimmune disease in this patient population

If untreated, risk for thrombosis and subsequent morbidity and/or mortality increases significantly.[2]

The HIT paradox: Patients treated with heparin may suffer a thrombosis as a consequence

The HIT Iceberg Model illustrates the concept that only a subset of patients on heparin develops thrombocytopenia, and only a subset of this population develops HIT.



On-demand HIT detection enhances patient care


Assess for HIT at first clinical suspicion

The 4Ts HIT Assessment Point System[3]


Points	2	1	0
Thrombocytopenia	Platelet-count fall >50% and platelet nadir >20 x 10^9/L	Platelet-count fall 30–50% or platelet nadir 10–19 x 10^9/L	Platelet-count fall <30% or platelet nadir <10 x 10^9/L
Timing of platelet-count fall	Clear onset between days 5–10 or platelet fall <1 day (prior heparin exposure within 30 days)	Consistent with days 5–10 fall, but not clear (e.g., missing platelet-count); onset after day 10; or fall <1 day (prior heparin exposure 30–100 days ago)	Platelet-count fall <4 days without recent exposure
Thrombosis or other sequelae	New thrombosis (confirmed); skin necrosis; acute systemic reaction post-I.V. UFH heparin bolus	Progressive or recurrent thrombosis; non-necrotizing (erythematous) skin lesions; suspected thrombosis (not proven)	None
OTher causes for thrombocytopenia	None apparent	Possible	Definite

Assign a point value to each 'T' and then total to determine 4Ts score (maximum 8): High = 6–8, Intermediate = 4–5, Low = 0–3

Platelet-Count Monitoring in 'Typical-onset HIT'[1]



- Rapid results from on-demand testing can aid in the exclusion or confirmation of HIT and help inform appropriate therapeutic decisions.



Rapid detection of HIT antibodies optimizes therapeutic decisions


HIT management challenges

- In some cases, HIT is assumed without the confirmation of laboratory results, leading to unnecessary therapeutic changes
- Alternative anticoagulants may:
  - Pose a patient-management challenge
  - Increase bleeding risk
  - Represent a difficult transition to warfarin (direct thrombin inhibitors can prolong prothrombin time)
  - Increase treatment cost
  - Increase length of stay (increase hospital costs)[4]

Excluding HIT can prevent unnecessary and labor-intensive changes in anticoagulant therapy in the majority of HIT-suspected cases.

On-demand Model for Anti-PF4-H Antibody Testing[5]

- Approximately 90% of HIT-suspected patients do not have HIT antibodies and are unlikely to develop HIT
- On-demand HIT antibody testing can prevent unnecessary and costly anticoagulant therapy changes in the majority of HIT-suspected cases




HEMOSIL

HIT-Ab$_{(PF4-H)}$ assay


Principle

HemosIL HIT-Ab$_{(PF4-H)}$ is a latex-enhanced immunoturbidimetric assay for the semi-quantitative detection of anti-PF4-H antibodies, commonly associated with HIT. The latex reagent is a suspension of polystyrene particles, coated with a monoclonal antibody against PF4-H. The competitive agglutination reaction occurs when a complex of PF4 and PVS (polyvinyl sulfonate, a compound similar to heparin) is mixed with the latex and patient sample. Anti-PF4-H in a positive sample will bind to the complex, inhibiting agglutination, while the absence of anti-PF4-H will allow the complex to bind to the latex, allowing agglutination.



Expected values

An expected values study evaluated 95% reference intervals in 131 healthy donors and 51 heparin-treated (non-HIT-suspected) patient samples. Healthy donor samples demonstrated a reference interval of 0–0.6 U/mL, and heparin-treated samples demonstrated a reference interval of 0–1.2 U/mL. Additionally, a comparison with the Serotonin Release assay (SRA) on 66 HIT-suspected patient samples indicated that the optimal cut-off (blue line), determined by receiver operating characteristic (ROC) analysis, was 1.0 U/mL (92.4% agreement). Based on these studies, HemosIL HIT-Ab$_{(PF4-H)}$ results ≥1.0 U/mL may indicate the presence of HIT antibodies.



Excellent correlation vs. ELISA

A multi-center study compared the HemosIL HIT-Ab$_{(PF4-H)}$ assay on the ACL TOP system versus a commercially available ELISA method. In 414 HIT-suspected samples, HIT-Ab$_{(PF4-H)}$ demonstrated a high degree of agreement with ELISA.

HemosIL HIT-Ab$_{(PF4-H)}$ vs. ELISA	
Co-negativity %	94.6 (91.5–96.7)
Co-positivity %	60.2 (48.9–70.8)
Overall %	87.7 (84.1–90.7)

Analytical performance on the ACL TOP® Family of Hemostasis Testing Systems

		Mean (U/mL)	CV% (Within run)	CV% (Total)
Precision	Low HIT-Ab Control	0.8	7.1	9.0
	High HIT-Ab Control	2.95	4.4	6.4
	Weakly Positive HIT-Ab Sample	1.6	4.9	8.1
	High HIT-Ab Sample	5.2	2.8	3.5
	Very High HIT-Ab Sample	10.0	5.5	9.5
Interferences	Hemoglobin		495 mg/dL	
	Bilirubin		18 mg/dL	
	Triglycerides		375 mg/dL	
	Rheumatoid Factor		1,000 IU/mL	
	Human Anti-Mouse Antibody		1 µg/mL	
	Antiphospholipid Antibodies		None	
Test Range	0–5.7 U/mL without rerun 0–16 U/mL with rerun			
Linearity	0.7–5.7 U/mL without rerun 2.1–16.0 U/mL with rerun			
Onboard Stability (of latex reagent, complex, stabilizer)	Continuous		36 hrs at 15°C	
	Cumulative (1 hr/day, then 2–8°C)		4 hrs over 120 days	
	Cumulative (2 hrs/day, then 2–8°C)		16 hrs over 15 days	
	Cumulative (4 hrs/day, then 2–8°C)		20 hrs over 9 days	

Automated HIT detection with ACL TOP Family 50 Series systems

A Breakthrough in Hemostasis Testing

ACL TOP 750/750 CTS/750 LAS

New ACL TOP Family 50 Series* systems deliver advanced automation and quality management for routine-to-specialty Hemostasis testing. Minimizing errors and enhancing quality, all models are standardized and offer automated pre-analytical sample integrity checks. Plus, all ACL TOP 50 Series systems are optimized for the comprehensive panel of HemosIL assays—offering complete disease-state management solutions.

All ACL TOP Family 50 systems offer:

- ***Same*** assay-specific pre-analytical sample checks
- ***Same*** advanced lab accreditation support
- ***Same*** advanced quality management

Plus the *same* standardized features of all ACL TOP systems:

- ***Same*** quality results
- ***Same*** comprehensive assay portfolio
- ***Same*** powerful and intuitive software
- ***Same*** features and usability



Advanced automation and quality for lab efficiency and better patient care.

*Not available in all countries.

HemosIL®

Product	Part Number	Kit Configuration
HIT-Ab$_{(PF4-H)}$	0020302700	2 x 1.8 mL Latex Reagent (liq) 2 x 0.8 mL Complex (liq) 2 x 3.2 mL Stabilizer (liq) 2 x 1 mL Calibrator (lyo)
HIT-Ab$_{(PF4-H)}$ Controls	0020013300	3 x 1 mL Low HIT-Ab$_{(PF4-H)}$ Control (liq) 3 x 1 mL High HIT-Ab$_{(PF4-H)}$ Control (liq)

References

1. Greinacher A, Althaus K, Krauel K, Selleng S. Heparin-induced thrombocytopenia. *Hämostaseologie*. 2010;1(Review):17–28.
2. Linkins L, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, et al. Treatment and Prevention of Heparin-Induced Thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2):495S–530S.
3. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4Ts) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thromb Haemost*. 2006;4:759.
4. Smythe MA, Koerber JM, Fitzgerald M, Mattson JC. The financial impact of heparin-induced thrombocytopenia. *Chest*. 2008;134(3):568–573.
5. Cuker A, Crowther M. 2013 Clinical practice guideline on the evaluation and management of adults with suspected heparin-induced thrombocytopenia (HIT). *Washington, DC: ASH (American Society of Hematology);*2013;4.
6. Greinacher A. Heparin-induced thrombocytopenia. *J Thromb Haemost*. 2009;7(Suppl. 1):9–12.
7. Greinacher A, Juhl D, Strobel U, Wessel A, Lubenow N, Selleng K, et al. Heparin-induced thrombocytopenia: a prospective study on the incidence, platelet-activating capacity and clinical significance of antiplatelet factor 4/heparin antibodies of the IgG, IgM, and IgA classes. *J Thromb Haemost*. 2007;5:1666–1673.

Additional literature

- Amiral J, Wolf M, Fischer A, Boyer-Neumann C, Vissac A, Meyer D. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. *Br J Haematol.* 1996;92(4):954–959.
- Althaus K, Hron G, Strobel U, Abbate R, Rogolino A, Davidson S, et al. Evaluation of automated immunoassays in the diagnosis of heparin induced thrombocytopenia. *Thromb Res.* 2013;131(3):e85–90.
- Davidson SJ, Ortel TL, Smith LJ. Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies. *Blood Coagul Fibrinolysis*. 2011;22(4):340–344.
- Greinacher A, Pötzsch B, Amiral J, Dummel V, Eichner A, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a molecular PF4-heparin complex as the major antigen. *J Thromb Haemost*. 1994;71(2):247–251.
- Morelli B, Novelli C, Grassi C, et al. Preliminary assessment of a new kit (HemosIL HIT-Ab$_{(PF4-H)}$) manufactured by Instrumentation Laboratory for the determination of anti-PF4/heparin antibodies. *Clin Chem Lab Med*. 2010;49(9):A183–A203.
- Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Eng J Med.* 1995;332(1):1330–1335.
- Warkentin TE, Sheppard JI, Linkins L, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay [HemosIL® HIT-Ab(PF4-H)] for the diagnosis of immune heparin-induced thrombocytopenia. *Thromb Res.* 2017;153:108–117.

Corporate Headquarters

Plaza de Europa, 21–23
08908 L'Hospitalet de Llobregat
Barcelona, Spain
+34-93-4010101

Hemostasis and Acute Care Diagnostics

Headquarters and Technology Center

180 Hartwell Road
Bedford, MA 01730-2443
USA
+1-781-861-0710

Worldwide Locations

The Americas

Brazil
São Paulo
+55-11-46227878

Canada
Richmond Hill, ON
+1-800-552-2025 x6115

Colombia
Bogotá
+57-15-221-052

Mexico
Mexico City
+52-55-5262-1760

Uruguay
Montevideo
+5982-481-81-33

USA
Bedford, MA
+1-781-861-0710

Asia-Pacific

Australia
Sydney
+61-02-9098-0200

China
Beijing
+86-10-59756055

Hong Kong
+852-2792-7773

Shanghai
+86-21-66308671

India
New Delhi
+91-490-29-550

Japan
Tokyo
+81-3-5419-1301

Korea
Seoul
+82-1899-9217

Thailand
Bangkok
+66-271-226-28/9

Europe

Austria
Vienna
+43-1-256-58-000

Belgium
Brussels
+32-2-7252052

Czech Republic
Prague
+420-246-090-931

France
Paris
+33-182-30-86-00

Germany
Munich
+49-89-909070

Hungary
Budapest
+36-1-882-73-10

Italy
Milan
+39-02-25221

Lithuania
Kaunas
+370-37-313157

The Netherlands
Breda
+31-76-5480100

Poland
Warsaw
+48-22-336-18-00

Portugal
Lisbon
+351-214247312

Russia
Moscow
+7-499-124-45-59

Spain
Barcelona
+34-902-20-30-90

UK
Warrington, England
+44-1925-810141

werfen.com

For more information, contact your local Werfen sales representative or distributor.

ACL, ACL AcuStar, ACL Elite, ACL TOP, HemoCell, HemoHub, HemosIL, ReadiPlasTin, RecombiPlasTin, SynthAFax and SynthASil are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. The Werfen logo is a trademark of Werfen and may be registered in the Patent and Trademark Offices of jurisdictions throughout the world. All other product names, company names, marks, logos and symbols are trademarks of their respective owners.

©2021 Instrumentation Laboratory. All rights reserved.

HIT Bro Rev00 WW 12/21

werfen